



Next Generation Topical Ophthalmics

Oculis to Present at the Upcoming 2020 Summer Private Company Showcase

LAUSANNE, Switzerland, August 7th, 2020 – Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, today announced that Riad Sherif M.D., CEO, will present a corporate update at the upcoming Summer Private Company Showcase 2020 hosted by Solebury Trout, Piper Sandler and White & Case. During the 20-minute presentation, participants will be able to submit questions electronically with answers provided at the discretion of the company on an individual basis afterwards.

Please click the following link to register: <https://troutaccess.com/index.php/c/Summer2020PCS>

Presentation Details:

Date: Monday, August 10, 2020

Time: 11:20am Eastern Time

About Oculis

Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients.

Oculis' novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.

The Company's leading clinical candidates include OCS-01 and OCS-02:

- OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone using Oculis' proprietary Solubilizing Nanoparticle (SNP) technology. It has successfully completed two Phase 2 clinical trials: in Diabetic Macular Edema (DME) and for treating inflammation and pain following cataract surgery. OCS-01 has the potential to provide the first non-invasive topical treatment option for DME patients and the first once a day, preservative free steroid for inflammation and pain following ocular surgery.
- OCS-02 is a novel topical anti-TNF alpha antibody and was in-licensed from Novartis. It has successfully completed two Phase 2 clinical trials in Acute Anterior Uveitis and in Dry Eye Disease.

In addition, Oculis' formulation discovery focus and capabilities are enabling the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.

Oculis has an experienced management team from global ophthalmic companies and is supported by leading international life science investors. Oculis is headquartered in Lausanne, Switzerland, with research operations in Iceland and France.

To learn more, visit www.ocularis.com

Contacts

Ocularis

Dr. Riad Sherif, CEO

riad.sherif@ocularis.com

Louie-Anne Gauthier, VP, Strategic Marketing and BD&L

louie-anne.gauthier@ocularis.com

Investor Relations

Burns McClellan

John Grimaldi

+1 212-213-0006 x362

jgrimaldi@burnsmc.com

Media Relations

Citigate Dewe Rogerson

Mark Swallow / Sylvie Berrebi

ocularis@citigatedewerogerson.com

+44 7903 737703 / +44 7714 306525